Anti-DPP9 antibody [EPR26469-62],Abcam,AB302903

Patented technology Our RabMAb ® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb ® patents . What are the advantages of a recombinant monoclonal antibody? This product is a recombinant monoclonal antibody, which offers several advantages including: - High batch-to-batch consistency and reproducibility - Improved sensitivity and specificity - Long-term security of supply - Animal-free batch production For more information, read more on recombinant antibodies .

Host

Rabbit

Reactivity

Human, Mouse, Rat

Application

WB, IP, IHC-P

Platform ID

BAB660394796

Abcam

Headquarters

Discovery Drive Cambridge Biomedical Campus Cambridge CB2 0AX UK

Contact

Tel: +44 (0)1223 696000
Fax: +44 (0)1223 215 215

Product Specifications
Scientific Background

Specifications

NameAnti-DPP9 antibody [EPR26469-62]
Cat. No.AB302903
HostRabbit
IsotypeIgG
ReactivityHuman, Mouse, Rat
ApplicationWB, IP, IHC-P
ClonalityMonoclonal
Clone NumberEPR26469-62
Concentration0.462 mg/mL Batch dependent concentration
ImmunogenThe exact immunogen used to generate this antibody is proprietary information.
PurityAffinity purification Protein A
Appearance/FormLiquid
ShippingBlue Ice
FormulationpH: 7.2 - 7.4 Preservative: 0.01% Sodium azide Constituents: PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA
Storage-20°C
Regulatory StatusResearch Use Only

Scientific Background

Target data Dipeptidyl peptidase that cleaves off N-terminal dipeptides from proteins having a Pro or Ala residue at position 2 (PubMed : 12662155, PubMed : 16475979, PubMed : 19667070, PubMed : 29382749, PubMed : 30291141, PubMed : 33731929, PubMed : 36112693). Acts as a key inhibitor of caspase-1-dependent monocyte and macrophage pyroptosis in resting cells by preventing activation of NLRP1 and CARD8 (PubMed : 27820798, PubMed : 29967349, PubMed : 30291141, PubMed : 31525884, PubMed : 32796818, PubMed : 36112693, PubMed : 36357533). Sequesters the cleaved C-terminal part of NLRP1 and CARD8, which respectively constitute the active part of the NLRP1 and CARD8 inflammasomes, in a ternary complex, thereby preventing their oligomerization and activation (PubMed : 33731929, PubMed : 33731932, PubMed : 34019797). The dipeptidyl peptidase activity is required to suppress NLRP1 and CARD8; however, neither NLRP1 nor CARD8 are bona fide substrates of DPP9, suggesting the existence of substrate(s) required for NLRP1 and CARD8 inhibition (PubMed : 33731929). See full target information DPP9

Category Paths

Request a product

Please provide the required information below so that we can quickly source your products.